New study tracks arthritis drug persistence in daily life
NCT ID NCT07532226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
guselkumab
What this could lead to
If successful, this study could show that guselkumab helps many patients with psoriatic arthritis stay on treatment longer, potentially improving disease control.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary by patient and may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopital Roger Salengro - CHU Lille
RECRUITINGLille, 59037, France